3B Blackbio DX Ltd

3B Blackbio Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

3B Blackbio DX Ltd

₹ 1,591 -1.82%
12 Jun - close price
kilpest.com BSE: 532067
About

Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]

Key Points

Business Segments[1][2]
A) Diagnostics Business (81% of FY23 revenue)
3BDL is part of an Indo-Spanish JV and was formed by amalgamation with its parent company Kilpest India Limited. Company is an ISO 13485:2016 certified, GMP-compliant biotech R&D organization and is engaged in the design, development, manufacturing, and commercialization of Rapid tests, PCR-based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, NGS-based Molecular Diagnostic Kit

Website BSE
  • Market Cap ₹ 1,366 Cr.
  • Current Price ₹ 1,591
  • High / Low ₹ 2,350 / 990
  • Stock P/E 28.7
  • Book Value ₹ 313
  • Dividend Yield 0.19 %
  • ROCE 25.8 %
  • ROE 19.4 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company has a good return on equity (ROE) track record: 3 Years ROE 16.8%

Cons

  • Dividend payout has been low at 5.42% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Service Provider

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
18.40 11.69 17.31 14.73 18.11 14.28 19.18 17.67 23.00 19.43 29.15 25.39 22.50
12.48 6.51 8.13 7.42 10.65 7.84 11.39 8.80 13.12 8.48 12.98 10.32 14.58
Operating Profit 5.92 5.18 9.18 7.31 7.46 6.44 7.79 8.87 9.88 10.95 16.17 15.07 7.92
OPM % 32.17% 44.31% 53.03% 49.63% 41.19% 45.10% 40.62% 50.20% 42.96% 56.36% 55.47% 59.35% 35.20%
1.87 1.24 1.96 2.88 1.15 2.96 2.75 2.63 4.19 3.69 3.44 3.01 4.94
Interest -0.02 0.03 0.07 0.05 0.04 0.02 0.04 0.03 0.04 0.01 0.03 0.02 0.04
Depreciation 0.17 0.17 0.24 0.25 0.21 0.19 0.24 0.32 0.30 0.27 0.27 0.27 0.28
Profit before tax 7.64 6.22 10.83 9.89 8.36 9.19 10.26 11.15 13.73 14.36 19.31 17.79 12.54
Tax % 36.91% 24.12% 23.27% 22.04% 37.80% 21.55% 26.02% 23.68% 35.98% 21.31% 22.99% 24.17% 35.89%
4.82 4.72 8.31 7.72 5.19 7.21 7.58 8.51 8.79 11.30 14.87 13.49 8.04
EPS in Rs 5.53 5.39 11.20 8.96 7.72 9.71 10.46 10.16 10.33 12.97 17.07 15.61 9.79
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
22 19 17 16 23 23 29 227 81 62 74 96
21 18 16 14 18 16 20 77 44 33 41 46
Operating Profit 1 1 2 3 5 7 9 150 37 29 33 50
OPM % 6% 7% 9% 16% 23% 31% 32% 66% 46% 47% 44% 52%
0 0 0 0 0 1 2 3 7 7 13 15
Interest 1 1 1 1 1 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 1 1 1 1 1 1 1
Profit before tax 0 0 0 1 5 7 10 152 43 35 44 64
Tax % 14% 23% 23% 19% 24% 25% 23% 25% 26% 27% 28% 25%
0 0 0 1 3 5 8 114 32 26 32 48
EPS in Rs 0.59 0.36 0.51 1.76 5.35 8.18 10.24 151.66 42.89 34.55 37.40 55.52
Dividend Payout % 0% 0% 0% 17% 9% 6% 7% 6% 24% 8% 8% 0%
Compounded Sales Growth
10 Years: 18%
5 Years: 27%
3 Years: 6%
TTM: 30%
Compounded Profit Growth
10 Years: 70%
5 Years: 44%
3 Years: 14%
TTM: 48%
Stock Price CAGR
10 Years: 69%
5 Years: 58%
3 Years: 66%
1 Year: 41%
Return on Equity
10 Years: 29%
5 Years: 30%
3 Years: 17%
Last Year: 19%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 6 6 6 6 6 6 7 7 7 9 9 9
Reserves 4 4 4 5 12 16 25 125 146 185 214 260
7 8 8 9 6 6 4 2 3 2 1 0
7 7 6 6 6 8 9 59 37 19 24 27
Total Liabilities 24 25 24 26 30 36 45 194 192 214 248 296
4 4 3 3 4 4 4 5 7 8 7 7
CWIP 0 0 0 0 0 0 0 0 0 0 0 0
Investments 0 0 0 0 0 0 1 59 93 92 117 156
20 21 21 22 26 32 40 130 93 114 123 132
Total Assets 24 25 24 26 30 36 45 194 192 214 248 296

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
0 0 1 1 2 4 7 98 37 20 27 43
-0 -0 -0 -0 -1 -1 -1 -70 -28 15 -20 -34
0 -0 -1 -0 0 -1 1 -2 -15 -5 -4 -3
Net Cash Flow 0 -0 0 0 1 2 7 26 -6 30 3 6

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 213 262 283 321 259 290 252 56 136 200 179 138
Inventory Days 120 145 143 175 164 141 124
Days Payable 189 218 203 186 69 66 28
Cash Conversion Cycle 144 188 223 310 259 290 252 56 136 296 253 235
Working Capital Days 218 274 312 377 308 351 302 67 169 248 216 169
ROCE % 7% 7% 7% 13% 24% 28% 31% 162% 27% 19% 21% 26%

Shareholding Pattern

Numbers in percentages

3 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
38.43% 38.43% 38.43% 38.43% 38.43% 38.43% 38.43% 41.29% 41.28% 41.28% 41.28% 41.28%
1.64% 1.64% 2.11% 2.54% 3.06% 3.16% 3.38% 2.97% 3.28% 3.27% 2.68% 2.49%
0.08% 0.00% 0.00% 0.00% 0.00% 0.82% 1.18% 1.89% 1.96% 1.96% 1.74% 1.60%
59.85% 59.94% 59.47% 59.02% 58.50% 57.60% 56.99% 53.85% 53.48% 53.48% 54.29% 54.64%
No. of Shareholders 16,31615,41513,79813,13612,41610,51310,0889,7539,3999,58610,16610,345

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls

  • May 2025
    Transcript
    Notes
    PPT
  • Feb 2025
    Transcript
    Notes
    PPT
  • Nov 2024
    Transcript
    Notes
    PPT
  • Aug 2024
    Transcript
    Notes
    PPT
  • May 2024
    Transcript
    Notes
    PPT
  • Feb 2024
    Transcript
    Notes
    PPT
  • Nov 2023
    Transcript
    Notes
    PPT
  • Aug 2023
    Transcript
    Notes
    PPT
  • May 2023
    Transcript
    Notes
    PPT
  • Feb 2023
    Transcript
    Notes
    PPT
  • Nov 2022
    Transcript
    Notes
    PPT
  • Sep 2022
    Transcript
    Notes
    PPT
  • Aug 2022
    Transcript
    Notes
    PPT
  • May 2022
    Transcript
    Notes
    PPT
  • Feb 2022
    Transcript
    Notes
    PPT
  • Nov 2021
    Transcript
    Notes
    PPT
  • Sep 2021
    Transcript
    Notes
    PPT
  • Jul 2021
    Transcript
    Notes
    PPT
  • Jun 2021
    Transcript
    Notes
    PPT
  • Feb 2021
    Transcript
    Notes
    PPT
  • Feb 2021
    Transcript
    Notes
    PPT
  • Nov 2020
    Transcript
    Notes
    PPT
  • Sep 2020
    Transcript
    Notes
    PPT
  • Jul 2020
    Transcript
    Notes
    PPT
  • Jun 2020
    Transcript
    Notes
    PPT
  • Feb 2020
    Transcript
    Notes
    PPT
  • Nov 2019
    Transcript
    Notes
    PPT
  • Jul 2019
    Transcript
    Notes
    PPT
  • May 2019
    Transcript
    Notes
    PPT
  • Jan 2019
    Transcript
    Notes
    PPT
  • Nov 2018
    Transcript
    Notes
    PPT
  • Aug 2018
    Transcript
    Notes
    PPT
  • May 2018
    Transcript
    Notes
    PPT
  • Feb 2018
    Transcript
    Notes
    PPT
  • Nov 2017
    Transcript
    Notes
    PPT
  • Jul 2017
    Transcript
    Notes
    PPT
  • Feb 2017
    Transcript
    Notes
    PPT